Recipharm launches into biologics manufacturing

Recently a Swedish biomanufacturing facility transfers from Astrazeneca to Recipharm Biologics.

By Sophia Carlsson

January 9, 2009 12:00 AM

Recipharm, one of

the leading contract development and manufacturing organisations, takes its first step into biologics manufacturing with the formal transfer of a majority stake in the Astrazeneca Biotech Laboratory, ABL, to its new subsidiary, Recipharm Biologics.

The transaction completed

on 1 January 2009. This modern facility adds mammalian recombinant protein and monoclonal antibody development and production capabilities to the group’s existing biopharmaceutical services.

Astrazeneca will

retain a significant minority stake in the new company and under the terms of the arrangement, Recipharm will lease the ABL from Astrazeneca for an initial period of 12 years, purchasing all associated equipment and employing the existing staff.

This latest purchase

follows the company’s recent acquisition of lyophilisation facilities from Inotech Labor. Combined, these enable Recipharm to offer a one-stop bio-manufacturing shop, taking customers’ projects from cell-line development based on their gene of interest, right through to their finished products for pre-clinical and early clinical studies.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.